Related Experiment Videos
Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells
Patrick Guensberg1, Volker Wacheck, Trevor Lucas
1Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, University of Vienna, Vienna, Austria.
Background:
Resistance to chemotherapy in glioblastoma has been linked to the expression of antiapoptotic Bcl-2 family members including Bcl-xL.
Methods:
Bcl-xL expression was specifically reduced in M059K glioblastoma cells with antisense oligonucleotides (ISIS 16009, ISIS 16967) as assessed by Western blotting. Induction of apoptosis by treatment with antisense oligonucleotides in combination with paclitaxel in cell culture was monitored by WST-1 assays and flow cytometric analysis.
Results:
Antisense oligonucleotide-mediated reduction of Bcl-xL levels led to enhanced cytotoxicity in M059K cells when compared to the use of a mismatch control oligonucleotide (p < 0.001). A decreased threshold for the induction of apoptosis led to significantly enhanced cytotoxic responses to paclitaxel treatment in WST-1 assays (p < 0.001) and flow cytometric analyses.
Conclusion:
Combination treatment using Bcl-xL antisense oligonucleotides and paclitaxel may qualify as a promising strategy to ultimately improve the clinical outcome of glioblastoma.
Insights
Targeting Bcl-xL with antisense oligonucleotides enhances glioblastoma cell sensitivity to paclitaxel. This combination therapy shows promise for improving glioblastoma treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Glioblastoma (GBM) exhibits resistance to chemotherapy.
- Overexpression of antiapoptotic Bcl-2 family proteins, such as Bcl-xL, contributes to this resistance.
Purpose of the Study:
- To investigate the efficacy of reducing Bcl-xL expression in glioblastoma cells.
- To evaluate the combined effect of Bcl-xL antisense oligonucleotides and paclitaxel on glioblastoma cell cytotoxicity.
Main Methods:
- Bcl-xL expression was suppressed in M059K glioblastoma cells using specific antisense oligonucleotides.
- Western blotting confirmed Bcl-xL reduction.
- Apoptosis induction and cytotoxicity were assessed using WST-1 assays and flow cytometry.
Main Results:
- Antisense-mediated Bcl-xL reduction significantly enhanced M059K cell cytotoxicity compared to control oligonucleotides (p < 0.001).
- The combination treatment lowered the threshold for apoptosis induction, leading to significantly increased cytotoxic responses to paclitaxel (p < 0.001).
Conclusions:
- Combining Bcl-xL antisense oligonucleotides with paclitaxel represents a potential therapeutic strategy.
- This approach may improve clinical outcomes for glioblastoma patients.